

## SUMMARY OF PRODUCT CHARACTERISTICS

### 1 NAME OF THE MEDICINAL PRODUCT

Bisoprolol 10mg film-coated Tablets

### 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Each Film coated tablet contains 10mg Bisoprolol Fumarate

For the full list of excipients, see section 6.1

### 3 PHARMACEUTICAL FORM

Film-coated tablet.

Pale to light orange, heart-shaped with a break-line on both sides, embossed "B 10" on one side.

The tablets can be divided into equal doses.

#### 4.1 Therapeutic indications

Treatment of Hypertension

Treatment of stable chronic angina

Treatment of stable chronic heart failure with reduced systolic left ventricular function in addition to ACE inhibitors, and diuretics, and optionally cardiac glycosides (for additional information see section 5.1).

#### 4.2 Posology and method of administration

##### Posology

##### *Treatment of hypertension and chronic stable angina pectoris:*

##### **Adults**

The dosage should be individually adjusted. It is recommended to start with 5 mg per day. The usual dose is 10 mg once daily with a maximum recommended dose of 20 mg per day.

##### **Renal impairment**

In patients with severe renal impairment (creatinine clearance < 20 ml/min) the dose should not exceed 10 mg once daily. This dosage may eventually be divided into halves.

##### **Severe hepatic impairment**

No dosage adjustment is required, however careful monitoring is advised.

**Elderly**

No dosage adjustment is normally required. It is recommended to start with the lowest possible dose.

***Paediatric population***

There is no experience with bisoprolol in children, therefore its use cannot be recommended for children.

**Discontinuation of treatment**

Treatment should not be stopped abruptly (see section 4.4). The dosage should be diminished slowly by a weekly halving of the dose.

**Treatment of stable chronic heart failure:****Adults**

Standard treatment of CHF consists of an ACE inhibitor (or an angiotensin receptor blocker in case of intolerance to ACE inhibitors), a beta-blocker, diuretics, and when appropriate cardiac glycosides. Patients should be stable (without acute failure) when bisoprolol treatment is initiated.

It is recommended that the treating physician should be experienced in the management of chronic heart failure.

Transient worsening of heart failure, hypotension, or bradycardia may occur during the titration period and thereafter.

**Titration phase**

The treatment of stable chronic heart failure with bisoprolol requires a titration phase. The treatment with bisoprolol is to be started with a gradual up-titration according to the following steps:

- 1.25 mg once daily for 1 week, if well tolerated increase to
- 2.5 mg once daily for a further week, if well tolerated increase to
- 3.75 mg once daily for a further week, if well tolerated increase to
- 5 mg once daily for the 4 following weeks, if well tolerated increase to
- 7.5 mg once daily for the 4 following weeks, if well tolerated increase to
- 10 mg once daily for the maintenance therapy

The maximum recommended dose is 10 mg once daily.

Close monitoring of vital signs (heart rate, blood pressure) and symptoms of worsening heart failure is recommended during the titration phase. Symptoms may already occur within the first day after initiating the therapy.

**Treatment modification**

If the maximum recommended dose is not well tolerated, gradual dose reduction may be considered.

In case of transient worsening of heart failure, hypotension, or bradycardia reconsideration of the dosage of the concomitant medication is recommended. It may also be necessary to temporarily lower the dose of bisoprolol or to consider discontinuation.

The reintroduction and/or uptitration of bisoprolol should always be considered when the patient becomes stable again.

If discontinuation is considered, gradual dose decrease is recommended, since abrupt withdrawal may lead to acute deterioration of the patients condition.

Treatment of stable chronic heart failure with bisoprolol is generally a long-term treatment.

### **Special population**

#### *Renal or hepatic impairment*

There is no information regarding pharmacokinetics of bisoprolol in patients with chronic heart failure and with impaired hepatic or renal function. Uptitration of the dose in these populations should therefore be made with additional caution.

#### *Elderly*

No dosage adjustment is required.

#### *Children*

There is no paediatric experience with bisoprolol, therefore its use cannot be recommended for children.

### **Method of Administration**

For oral use.

Bisoprolol tablets should be taken in the morning and can be taken with food. They should be swallowed with liquid and should not be chewed.

## **4.3 Contraindications**

Bisoprolol is contraindicated in chronic heart failure patients with:

- acute heart failure or during episodes of heart failure decompensation requiring i.v. inotropic therapy
- cardiogenic shock
- second or third degree AV block (without a pacemaker)
- sick sinus syndrome
- sinoatrial block
- symptomatic bradycardia
- symptomatic hypotension
- severe bronchial asthma or severe chronic obstructive pulmonary disease
- late stages of peripheral arterial occlusive disease and Raynaud's syndrome
- untreated phaeochromocytoma (see 4.4)
- metabolic acidosis
- hypersensitivity to bisoprolol or to any of the excipients listed in section 6.1

## **4.4 Special warnings and precautions for use**

Special Warnings

***Applies only to chronic heart failure:***

The treatment of stable chronic heart failure with bisoprolol has to be initiated with a special titration phase (see section 4.2).

***Applies to all indications:***

Especially in patients with ischaemic heart disease the cessation of therapy with bisoprolol must not be done abruptly unless clearly indicated, because this may lead to transitional worsening of heart condition (see section 4.2).

Precautions

***Applies only to hypertension or angina pectoris:***

Bisoprolol must be used with caution in patients with hypertension or angina pectoris and accompanying heart failure.

***Applies only to chronic heart failure:***

The initiation and cessation of treatment of stable chronic heart failure with bisoprolol necessitates regular monitoring. For the posology and method of administration please refer to section 4.2.

There is no therapeutic experience of bisoprolol treatment of heart failure in patients with the following diseases and conditions:

- insulin dependent diabetes mellitus (type I)
- severely impaired renal function
- severely impaired hepatic function
- restrictive cardiomyopathy
- congenital heart disease
- haemodynamically significant organic valvular disease
- myocardial infarction within 3 months

***Applies to all indications:***

Bisoprolol must be used with caution in:

- bronchospasm (bronchial asthma, obstructive airways diseases). In bronchial asthma or other chronic obstructive lung diseases, which may cause symptoms, broncho dilating therapy is recommended to be given concomitantly. Occasionally an increase of the airway resistance may occur in patients with asthma, therefore the dose of beta2- stimulants may have to be increased.
- diabetes mellitus with large fluctuations in blood glucose values; symptoms of (e.g. tachycardia, palpitations or sweating) hypoglycaemia can be masked. Beta-blockers could further increase the risk of severe hypoglycaemia when used concurrently with sulfonylureas. Diabetic patients should be advised to carefully monitor blood glucose levels (see Section 4.5).
- strict fasting
- ongoing desensitisation therapy. As with other beta-blockers, bisoprolol may increase both the sensitivity towards allergens and the severity of anaphylactic reactions. Epinephrine treatment does not always yield the expected therapeutic effect.
- first degree AV block
- Prinzmetal's angina: Cases of coronary vasospasm have been observed. Despite its high beta1-selectivity, angina attacks cannot be completely excluded when bisoprolol is administered to patients with Prinzmetal's angina.
- peripheral arterial occlusive disease (intensification of complaints might happen especially during the start of therapy)
- general anaesthesia

In patients undergoing general anaesthesia beta-blockade reduces the incidence of arrhythmias and myocardial ischemia during induction and intubation, and the post-operative period. It is currently recommended that maintenance beta-blockade be continued peri-operatively. The anaesthetist must be aware of beta-blockade because of the potential for interactions with other drugs, resulting in bradyarrhythmias, attenuation of the reflex tachycardia and the decreased reflex ability to compensate for blood loss. If it is thought necessary to withdraw beta-blocker therapy before surgery, this should be done gradually and completed about 48 hours before anaesthesia.

Combination of bisoprolol with calcium antagonists of the verapamil or diltiazem type, with Class I antiarrhythmic drugs and with centrally acting antihypertensive drugs is generally not recommended, for details please refer to section 4.5.

Although cardioselective (beta1) beta-blockers may have less effect on lung function than non-selective betablockers, as with all beta-blockers, these should be avoided in patients with obstructive airways diseases, unless there are compelling clinical reasons for their use. Where such reasons exist, Bisoprolol may be used with caution. In patients with obstructive airways diseases, the treatment with bisoprolol should be started at the lowest possible dose and patients should be carefully monitored for new symptoms (e.g. dyspnea, exercise intolerance, cough). In bronchial asthma or other chronic obstructive lung diseases, which may cause symptoms, bronchodilating therapy should be given concomitantly. Occasionally an increase of the airway resistance may occur in patients with asthma, therefore the dose of beta2-stimulants may have to be increased.

Patients with psoriasis or with a history of psoriasis should only be given beta-blockers (e.g. bisoprolol) after carefully balancing the benefits against the risks.

In patients with phaeochromocytoma bisoprolol must not be administered until after alpha-receptor blockade.

Under treatment with bisoprolol the symptoms of a thyreotoxicosis may be masked.

## **4.5 Interaction with other medicinal products and other forms of interaction**

### **Combinations not recommended**

#### ***Applies only to chronic heart failure:***

Class I antiarrhythmic drugs (e.g. quinidine, disopyramide; lidocaine, phenytoin; flecainide, propafenone): Effect on atrio-ventricular conduction time may be potentiated and negative inotropic effect increased.

#### ***Applies to all indications:***

Calcium antagonists of the verapamil type and to a lesser extent of the diltiazem type: Negative influence on contractility and atrio-ventricular conduction. Intravenous administration of verapamil in patients on  $\beta$ -blocker treatment may lead to profound hypotension and atrioventricular block.

Centrally acting antihypertensive drugs such as clonidine and others (e.g. methyl dopa, moxonidine, rilmenidine): Concomitant use of centrally acting antihypertensive drugs may worsen heart failure by a decrease in the central sympathetic tonus (reduction of heart rate and cardiac output, vasodilation). Abrupt

withdrawal, particularly if prior to beta-blocker discontinuation, may increase risk of “rebound hypertension”.

### **Combinations to be used with caution**

#### **Applies only to hypertension or angina pectoris:**

Class-I antiarrhythmic drugs (e.g. quinidine, disopyramide; lidocaine, phenytoin; flecainide propafenone): Effect on atrioventricular conduction time may be potentiated and negative inotropic effect increased.

#### **Applies to all indications**

Calcium antagonists of the dihydropyridine type such as felodipine and amlodipine: Concomitant use may increase the risk of hypotension, and an increase in the risk of a further deterioration of the ventricular pump function in patients with heart failure cannot be excluded.

Class-III antiarrhythmic drugs (e.g. amiodarone): Effect on atrio-ventricular conduction time may be potentiated.

Topical beta-blockers (e.g. eye drops for glaucoma treatment) may add to the systemic effects of bisoprolol.

Parasympathomimetic drugs: Concomitant use may increase atrio-ventricular conduction time and the risk of bradycardia.

Insulin and oral antidiabetic drugs: Intensification of blood sugar lowering effect. Blockade of beta-adrenoreceptors may mask symptoms of hypoglycaemia. The concomitant use of beta-blockers with sulfonylureas could increase the risk of severe hypoglycaemia (see Section 4.4).

Anaesthetic agents: Attenuation of the reflex tachycardia and increase of the risk of hypotension (for further information on general anaesthesia see also section 4.4.).

Digitalis glycosides: Reduction of heart rate, increase of atrio-ventricular conduction time.

Non-steroidal anti-inflammatory drugs (NSAIDs): NSAIDs may reduce the hypotensive effect of bisoprolol.

$\beta$ -Sympathomimetic agents (e.g. isoprenaline, dobutamine): Combination with bisoprolol may reduce the effect of both agents.

Sympathomimetics that activate both  $\beta$ - and  $\alpha$ -adrenoceptors (e.g. noradrenaline, adrenaline): Combination with bisoprolol may unmask the  $\alpha$ -adrenoceptor-mediated vasoconstrictor effects of these agents leading to blood pressure increase and exacerbated intermittent claudication. Such interactions are considered to be more likely with nonselective  $\beta$ -blockers.

Concomitant use with antihypertensive agents as well as with other drugs with blood pressure lowering potential (e.g. tricyclic antidepressants, barbiturates, phenothiazines) may increase the risk of hypotension.

### **Combinations to be considered**

Mefloquine: increased risk of bradycardia

Monoamine oxidase inhibitors (except MAO-B inhibitors): Enhanced hypotensive effect of the beta-blockers but also risk for hypertensive crisis.

Rifampicin: Slight reduction of the half-life of bisoprolol possible due to the induction of hepatic drug metabolising enzymes. Normally no dosage adjustment is necessary.

Ergotamine derivatives: Exacerbation of peripheral circulatory disturbances.

## **4.6 Fertility, pregnancy and lactation**

### ***Pregnancy:***

Bisoprolol has pharmacological effects that may cause harmful effects on pregnancy and/or the fetus/newborn. In general, beta-adrenoceptor blockers reduce placental perfusion, which has been associated with growth retardation, intrauterine death, abortion or early labour. Adverse effects (e.g. hypoglycaemia and bradycardia) may occur in the fetus and newborn infant. If treatment with beta-adrenoceptor blockers is necessary, beta<sub>1</sub>-selective adrenoceptor blockers are preferable.

Bisoprolol should not be used during pregnancy unless clearly necessary. If treatment with bisoprolol is considered necessary, the uteroplacental blood flow and the fetal growth should be monitored. In case of harmful effects on pregnancy or the fetus alternative treatment should be considered. The newborn infant must be closely monitored. Symptoms of hypoglycaemia and bradycardia are generally to be expected within the first 3 days.

### ***Breast-feeding:***

It is not known whether this drug is excreted in human milk. There are no data on the safety of bisoprolol exposure in infants. Therefore, breastfeeding is not recommended during administration of bisoprolol.

### ***Fertility:***

In reproduction toxicology studies Bisoprolol had no influence on fertility or on general reproduction performance (see section 5.3).

## **4.7 Effects on ability to drive and use machines**

In a study with coronary heart disease patients bisoprolol did not impair driving performance. However, due to individual variations in reactions to the drug, the ability to drive a vehicle or to operate machinery may be impaired. This should be considered particularly at start of treatment and upon change of medication as well as in conjunction with alcohol.

## **4.8 Undesirable effects**

The following definitions apply to the frequency terminology used

hereafter: Very common ( $\geq 1/10$ )

Common ( $\geq 1/100$ ,  $< 1/10$ )  
Uncommon ( $\geq 1/1,000$ ,  $< 1/100$ )  
Rare ( $\geq 1/10,000$ ,  $< 1/1,000$ )  
Very rare ( $< 1/10,000$ )  
Frequency not known (cannot be estimated from available data)

Cardiac disorders:

Very common: bradycardia.  
Common: worsening of heart failure.  
Uncommon: AV-conduction disturbances.

Investigations:

Rare: increased triglycerides, increased liver enzymes (ALAT, ASAT).

Nervous system disorders:

Common: dizziness, headache.  
Rare: syncope

Eye disorders:

Rare: reduced tear flow (to be considered if the patient uses lenses).  
Very rare: conjunctivitis.

Ear and labyrinth disorders:

Rare: hearing impairment.

Respiratory, thoracic and mediastinal disorders:

Uncommon: bronchospasm in patients with bronchial asthma or a history of obstructive airways disease.  
Rare: allergic rhinitis.

Gastrointestinal disorders:

Common: gastrointestinal complaints such as nausea, vomiting, diarrhoea, constipation.

Skin and subcutaneous tissue disorders:

Rare: hypersensitivity reactions (pruritus, itching, flush, rash and angioedema).  
Very rare: beta-blockers may provoke or worsen psoriasis or induce psoriasis-like rash, alopecia.

Musculoskeletal and connective tissue disorders:

Uncommon: muscular weakness and cramps.

Vascular disorders:

Common: feeling of coldness or numbness in the extremities, hypotension.  
Uncommon: orthostatic hypotension.

General disorders:

Common: asthenia, fatigue.

Hepatobiliary disorders:

Rare: hepatitis.

Reproductive system and breast disorders:

Rare: erectile dysfunction.

#### Psychiatric disorders:

Uncommon: sleep disorders, depression.

Rare: nightmares, hallucinations.

#### Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard) or search for MHRA Yellow Card in the Google Play or Apple App Store.

## **4.9 Overdose**

### Symptoms

With overdose (e.g. daily dose of 15 mg instead of 7.5 mg) third degree AV-block, bradycardia, and dizziness have been reported. In general the most common signs expected with overdosage of a beta-blocker are bradycardia, hypotension, bronchospasm, acute cardiac insufficiency and hypoglycaemia. To date a few cases of overdose (maximum: 2000 mg) with bisoprolol have been reported in patients suffering from hypertension and/or coronary heart disease showing bradycardia and/or hypotension; all patients recovered. There is a wide interindividual variation in sensitivity to one single high dose of bisoprolol and patients with heart failure are probably very sensitive. Therefore it is mandatory to initiate the treatment of these patients with a gradual uptitration according to the scheme given in section 4.2.

### Management

If overdose occurs, bisoprolol treatment should be stopped and supportive and symptomatic treatment should be provided. Limited data suggest that bisoprolol is hardly dialysable. Based on the expected pharmacologic actions and recommendations for other beta-blockers, the following general measures should be considered when clinically warranted.

**Bradycardia:** Administer intravenous atropine. If the response is inadequate, isoprenaline or another agent with positive chronotropic properties may be given cautiously. Under some circumstances, transvenous pacemaker insertion may be necessary.

**Hypotension:** Intravenous fluids and vasopressors should be administered. Intravenous glucagon may be useful.

**AV block (second or third degree):** Patients should be carefully monitored and treated with isoprenaline infusion or transvenous cardiac pacemaker insertion.

**Acute worsening of heart failure:** Administer i.v. diuretics, inotropic agents, vasodilating agents.

**Bronchospasm:** Administer bronchodilator therapy such as isoprenaline, beta<sub>2</sub>-sympathomimetic drugs and/or aminophylline.

**Hypoglycaemia:** Administer i.v. glucose.

## 5 PHARMACOLOGICAL PROPERTIES

### 5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Beta blocking agents, selective

ATC Code: C07AB07

#### Mechanism of action

Bisoprolol is a highly beta<sub>1</sub>-selective-adrenoceptor blocking agent, lacking intrinsic stimulating and relevant membrane stabilising activity. It only shows low affinity to the beta<sub>2</sub>-receptor of the smooth muscles of bronchi and vessels as well as to the beta<sub>2</sub>-receptors concerned with metabolic regulation. Therefore, bisoprolol is generally not to be expected to influence the airway resistance and beta<sub>2</sub>-mediated metabolic effects. Its beta<sub>1</sub>-selectivity extends beyond the therapeutic dose range.

#### Clinical efficacy and safety

In total 2647 patients were included in the CIBIS II trial. 83% (n = 2202) were in NYHA class III and 17% (n = 445) were in NYHA class IV. They had stable symptomatic systolic heart failure (ejection fraction  $\leq 35\%$ , based on echocardiography). Total mortality was reduced from 17.3% to 11.8% (relative reduction 34%). A decrease in sudden death (3.6% vs 6.3%, relative reduction 44%) and a reduced number of heart failure episodes requiring hospital admission (12% vs 17.6%, relative reduction 36%) was observed. Finally, a significant improvement of the functional status according to NYHA classification has been shown. During the initiation and titration of bisoprolol hospital admission due to bradycardia (0.53%), hypotension (0.23%), and acute decompensation (4.97%) were observed, but they were not more frequent than in the placebo-group (0%, 0.3% and 6.74%). The numbers of fatal and disabling strokes during the total study period were 20 in the bisoprolol group and 15 in the placebo group.

The CIBIS III trial investigated 1010 patients aged  $\geq 65$  years with mild to moderate chronic heart failure (CHF; NYHA class II or III) and left ventricular ejection fraction  $\leq 35\%$ , who had not been treated previously with ACE inhibitors, beta-blockers, or angiotensin receptor blockers. The trial compared the efficacy and safety of an initial six-month monotherapy with bisoprolol (target dose 10 mg once daily), to which the ACE inhibitor enalapril (target dose 10 mg twice daily) was added for further 6 to 24 months, with the opposite sequence of treatment initiation. Each group comprised 505 patients.

The two strategies were blindly compared with regard to the combined primary endpoint of all-cause mortality or hospitalisation, and each of these components individually. In the intention-to-treat population the primary endpoint occurred in 178 patients (35.2%) in the bisoprolol-first group vs. 186 (36.8%) in the enalapril-first group, showing bisoprolol-first treatment to be comparably effective (non-inferior) as enalapril-first treatment. With bisoprolol-first, 65 patients died vs. 73 with enalapril-first (between-group difference  $p=0.44$ ), and 151 vs. 157 patients were hospitalised ( $p=0.66$ ). The number of serious and total adverse events was similar in the two groups. Analysis of data from the first year showed a non-significant trend of the bisoprolol-first strategy to reduce all-cause mortality by 31% compared with the enalapril-first strategy. Mainly the statistically significant risk-reduction of sudden death by 46% ( $p=0.049$ ) during the first year contributed to the better survival in the bisoprolol-first group.

The two strategies for initiation of CHF treatment showed a similar rate of combined death and hospitalization, and a trend towards prolonged survival, particularly by reduction of sudden death, was observed in the bisoprolol-first group. The results indicate that it is as safe and efficacious to initiate treatment for CHF with bisoprolol as with enalapril.

Bisoprolol is also used for the treatment of hypertension and angina.

In acute administration in patients with coronary heart disease without chronic heart failure bisoprolol reduces the heart rate and stroke volume and thus the cardiac output and oxygen consumption. In chronic administration the initially elevated peripheral resistance decreases.

## **5.2 Pharmacokinetic properties**

### Absorption

Bisoprolol is absorbed and has a biological availability of about 90% after oral administration.

### Distribution

The distribution volume is 3.5 l/kg. The plasma protein binding of bisoprolol is about 30%.

### Biotransformation and Elimination

Bisoprolol is excreted from the body by two routes. 50% is metabolised by the liver to inactive metabolites which are then excreted by the kidneys. The remaining 50% is excreted by the kidneys in an unmetabolised form. Total clearance is approximately 15 l/h. The half-life in plasma of 10-12 hours gives a 24 hour effect after dosing once daily.

### Linearity

The kinetics of bisoprolol are linear and independent of age.

### Special population

Since the elimination takes place in the kidneys and the liver to the same extent a dosage adjustment is not required for patients with impaired liver function or renal insufficiency. The pharmacokinetics in patients with stable chronic heart failure and with impaired liver or renal function has not been studied. In patients with chronic heart failure (NYHA stage III) the plasma levels of bisoprolol are higher and the half-life is prolonged compared to healthy volunteers. Maximum plasma concentration at steady state is  $64 \pm 21$  ng/ml at a daily dose of 10 mg and the half-life is  $17 \pm 5$  hours.

## **5.3 Preclinical safety data**

Preclinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity or carcinogenicity. Like other beta-blockers, bisoprolol caused maternal (decreased food intake and decreased body weight) and embryo/fetal toxicity (increased incidence of resorptions, reduced birth weight of the offspring, retarded physical development) at high doses but was not teratogenic.

## **6 PHARMACEUTICAL PARTICULARS**

### **6.1 List of excipients**

Microcrystalline Cellulose (PH-112)  
Maize Starch  
Crospovidone (Type B)  
Colloidal Anhydrous Silica  
Magnesium Stearate  
Purified Water  
Hypromellose  
Macrogol 400  
Titanium dioxide (E171)  
Ferric oxide yellow (E172)  
Ferric oxide red (E172)

### **6.2 Incompatibilities**

Not applicable.

### **6.3 Shelf life**

3 years.

### **6.4 Special precautions for storage**

No special requirements

### **6.5 Nature and contents of container**

20, 28, 30, 50, 56, 60, 90, or 100 tablets

Not all pack sizes are marketed.

Tablets are packed in Aluminium (0.02mm thickness) and PVC (0.25mm)/ PVDC (120 gsm) blisters.

Blisters are packed in cartons.

### **6.6 Special precautions for disposal**

No special requirements.

**7      MARKETING AUTHORISATION HOLDER**

Noumed Life Sciences Limited  
Noumed House  
Shoppenhangers Road  
Maidenhead  
Berkshire  
SL6 2RB  
United Kingdom

**8      MARKETING AUTHORISATION NUMBER(S)**

PL 44041/0005

**9      DATE OF FIRST AUTHORISATION/RENEWAL OF THE  
AUTHORISATION**

27/01/2025

**10     DATE OF REVISION OF THE TEXT**

26/09/2025